Summit Therapeutics (SMMT) Current Assets (2018 - 2026)

Summit Therapeutics (SMMT) has reported Current Assets for 9 consecutive years, with $720.6 million the latest figure, recorded in Q2 2026.

• Quarterly Current Assets rose 133.02% year-over-year to $720.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $720.6 million (up 133.02% YoY) and the FY2025 annual result came in at $720.3 million, up 69.98% from the prior year.
• Current Assets grew to $720.6 million in Q2 2026 per SMMT's latest filing, from $616.6 million in the prior quarter.
• Over the last five years, Current Assets for SMMT reached as high as $720.6 million in Q2 2026 and fell as low as $79.4 million in Q2 2022.
• A 5-year average of $346.3 million and a median of $278.6 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets soared 574.85% — and 2023, when it tumbled 71.11%.
• Year by year, Current Assets stood at $656.7 million in 2022, then slumped by 71.11% to $189.7 million in 2023, then surged by 123.36% to $423.8 million in 2024, then surged by 69.98% to $720.3 million in 2025, then climbed by 0.04% to $720.6 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $720.6 million, $616.6 million, and $720.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.